AMR SVG Icons location

VasopressinInjection, USP


  • Vial closure is not made with natural rubber latex
  • Formulated, filled, and finished in our US-based manufacturing facilities

Receive Availability Emails

  Pack NDC# Strength Supplied As Shelf Pack Vial Opening Size Product Info Availability
Strength:

20 Units/mL

Supplied As:

1 mL
Single Dose Vial

NDC#: 0517-1020-25
0517-1020-25

20 Units/mL

1 mL
Single Dose Vial

25 13 mm Limited Availability
  • Shelf Pack 25
  • Availability Limited Availability

Contains 5 mg/mL chlorobutanol as a preservative

Wholesaler Numbers

  • ABC 10264598
  • Cardinal 1652452
  • McKesson 1613744
  • Morris & Dickson 198762

Case Information

  • Unit of Sale NDC 0517-1020-25
  • Order Size 25
  • Case Size 24
  • Case Per Tier 110

Contact Us

Request for Medical Information Request a Grant Investigator Initiated Study Request a Certificate of Analysis Expanded Access Policy
Please choose your preferred method of contact

By clicking Submit, you confirm that you accept our Privacy Policy and that you agree to your personal contact information being used to contact you and added to our database. If at any time you wish your personal information to be removed from the American Regent® database, please submit a message request to corpcommunications@americanregent.com.

Vasopressin Injection, USP

For intravenous use. Dilute prior to administration.

INDICATIONS AND USAGE
Vasopressin injection is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS
Vasopressin injection is contraindicated in patients with known allergy or hypersensitivity to 8-L-arginine vasopressin or chlorobutanol.

WARNINGS AND PRECAUTIONS
Can worsen cardiac function.
Patients may experience reversible diabetes insipidus.

ADVERSE REACTIONS
The most common adverse reactions included decreased cardiac output, bradycardia, tachyarrhythmias, hyponatremia, and ischemia (coronary, mesenteric, skin, digital).

The following additional adverse reactions were identified:

Bleeding/lymphatic system disorders: Hemorrhagic shock, decreased platelets, intractable bleeding

Cardiac disorders: Right heart failure, atrial fibrillation, bradycardia, myocardial ischemia

Hepatobiliary: Increased bilirubin levels

Renal/urinary disorders: Acute renal insufficiency

Vascular disorders: Distal limb ischemia

DRUG INTERACTIONS
Hemodynamic monitoring is recommended; adjust the dose of vasopressin as needed.

USE IN SPECIFIC POPULATIONS
Pregnancy: May induce tonic uterine contractions.

Pediatric Use: Safety and effectiveness have not been established.

Geriatric Use: Dose selection for an elderly patient should be cautious.

For additional safety information, please see Full Prescribing Information.

You are encouraged to report adverse drug events to American Regent, Inc. at 1-800-734-9236 or to the FDA by visiting www.fda.gov/medwatch or calling 1-800-FDA-1088.